The effects of weekly alendronate therapy in Taiwanese males with osteoporosis

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 3, 2010, Pages 328-333

  Hwang, Jawl Shan ^a   Liou, Miaw Jene ^a   Ho, Cheng ^a   Lin, Jen Der ^a   Huang, Yu Yao ^a   Wang, Chao Jan ^a   Tsai, Keh Sung ^b   Chen, Jung Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Alendronate; Bone mineral density; Male osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM CARBONATE; CALCIUM PHOSPHATE; COLECALCIFEROL; DEOXYPYRIDINOLINE; ALKALINE PHOSPHATASE; AMINO ACID; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; ISOENZYME;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; LUMBAR SPINE; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TAIWAN; URINARY EXCRETION; BLOOD; BODY MASS; BONE REMODELING; CHEMISTRY; DRUG EFFECT; FEMUR NECK; LUMBAR VERTEBRA; MIDDLE AGED; PHOTON ABSORPTIOMETRY; TIME; URINE;

ABSORPTIOMETRY, PHOTON; ALENDRONATE; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FEMUR NECK; HUMANS; ISOENZYMES; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; TAIWAN; TIME FACTORS;

EID: 77956037315     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0136-9     Document Type: Article

References (25)

1. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767
2. Tsai KS (1997) Osteoporotic fracture rate, bone mineral density, and bone metabolism in Taiwan. J Formos Med Assoc 96:802-805
3. Hwang JS, Tu ST, Yang TS, Chen JF, Wang CJ, Tsai KS (2006) Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 17:373-378
4. Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338:736-746
5. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578
6. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12:1761-1768
7. Cooper C, Campion G, Melton LJ III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285-289
8. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010-1018
9. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516
10. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging Clin Exp Res 12:1-12
11. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
12. Ringe JD, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86:5252-5255
13. Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M, Gennari L, Gennari C, Nuti R (2003) Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 73:133-139
14. Ringe JD, Orwoll E, Daifotis A, Lombardi A (2002) Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13:195-199
15. Sawka AM, Thabane L, Papaioannou A, Gafni A, Hanley DA, Adachi JD (2005) A systematic review of the effect of alendronate on bone mineral density in men. J Clin Densitom 8:7-13
16. Rizzoli R, Greenspan SL, Bone G III, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group (2002) Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988-1996
17. Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152
18. Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with longterm changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762-2767
19. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
20. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10:183-192
21. Lau EM, Woo J, Chan YH, Griffith J (2000) Alendronate prevents bone loss in Chinese women with osteoporosis. Bone 27:677-680
22. Yen ML, Yen BL, Jang MH, Hsu SH, Cheng WC, Tsai KS (2000) Effects of alendronate on osteopenic postmenopausal Chinese women. Bone 27:681-685
23. Ho AY, Kung AW (2005) Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother 39:1428-1433
24. Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382-388
25. Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F (2009) The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. J Bone Mineral Metab 27:471-478